github link
Accession IconGSE88886

Pharmacodynamic-induced changes in SLE Patients from the ILLUMINATE-2 phase III trial of B cell activating factor blockade with tabalumab

Organism Icon Homo sapiens
Sample Icon 414 Downloadable Samples
Technology Badge Icon Affymetrix Human Transcriptome Array 2.0 (hta20)

Submitter Supplied Information

Description
Objective: Systemic lupus erythematosus (SLE) has substantial unmet medical need and its pathogenesis is incompletely understood. This study characterized baseline gene expression and pharmacodynamic (PD)-induced changes in whole blood gene expression from two phase III, 52-week (W), randomized, placebo-controlled, double-blind studies of 1,760 SLE patients treated with the B cell activating factor (BAFF)-blocking IgG4 monoclonal antibody, tabalumab. Methods: Patient samples were obtained from ILLUMINATE-1 and -2 while control samples were from healthy donors. Blood was collected in TempusTM tubes at baseline, W16 and W52. RNA was analyzed using the Affymetrix Human Transcriptome Array 2.0 and NanoStringTM. Results: At baseline there was elevation of interferon responsive genes (IRG) in patients compared to controls, with 75% positive for this IRG signature. There was, however, substantial heterogeneity of IRG expression and complex relationships among gene networks. The interferon signature was a predictor of future time to flare, independent of anti-double stranded DNA antibody (dsDNA), C3 and C4 levels, and overall disease activity. PD changes in gene expression following tabalumab treatment were extensive, occurring predominantly in B cell-related and immunoglobulin (Ig) genes, and were consistent with other PD-induced changes including dsDNA, C3, and Ig levels. Conclusions: SLE patients demonstrated elevated expression of an IRG signature, detected in 75% of the patients at baseline in ILLUMINATE-1 and -2. There was substantial heterogeneity of gene expression detected among individual patients and in gene networks. The interferon signature was an independent risk factor for future flares. PD changes in gene expression were consistent with the mechanism of BAFF blockade by tabalumab.
PubMed ID
Total Samples
418
Submitter’s Institution

Samples

Show of 418 Total Samples
Filter
Add/Remove
Accession Code
Title
Sex
Specimen part
Race
Subject
Time
Processing Information
Additional Metadata
SUBJ.0496, SLE, baseline
female
blood
white
subj.0496
baseline
SUBJ.0998, SLE, week16
male
blood
white
subj.0998
week16
SUBJ.0112, SLE, week16
female
blood
white
subj.0112
week16
SUBJ.1195, SLE, baseline
female
blood
white
subj.1195
baseline
SUBJ.0313, SLE, week16
female
blood
white
subj.0313
week16
SUBJ.1653, SLE, week16
female
blood
white
subj.1653
week16
SUBJ.1298, SLE, week16
female
blood
white
subj.1298
week16
SUBJ.0829, SLE, week52
female
blood
white
subj.0829
week52
SUBJ.1735, SLE, week16
female
blood
white
subj.1735
week16
SUBJ.1653, SLE, week52
female
blood
white
subj.1653
week52
Loading...